COVER
COVER - shares | 3 Months Ended | |
Mar. 31, 2024 | May 01, 2024 | |
Cover [Abstract] | ||
Document Type | 10-Q | |
Document Quarterly Report | true | |
Document Period End Date | Mar. 31, 2024 | |
Document Transition Report | false | |
Entity File Number | 001-36421 | |
Entity Registrant Name | Aurinia Pharmaceuticals Inc. | |
Entity Incorporation, State or Country Code | Z4 | |
Entity Address, Address Line One | #140, 14315 - 118 Avenue | |
Entity Address, City or Town | Edmonton | |
Entity Address, State or Province | AB | |
Entity Address, Postal Zip Code | T5L 4S6 | |
Entity Tax Identification Number | 98-1231763 | |
City Area Code | (250) | |
Local Phone Number | 744-2487 | |
Entity Current Reporting Status | Yes | |
Entity Interactive Data Current | Yes | |
Entity Filer Category | Large Accelerated Filer | |
Entity Small Business | false | |
Entity Emerging Growth Company | false | |
Entity Shell Company | false | |
Entity Common Stock, Shares Outstanding | 143,019,365 | |
Title of 12(b) Security | Common shares, no par value | |
Trading Symbol | AUPH | |
Security Exchange Name | NASDAQ | |
Amendment Flag | false | |
Document Fiscal Year Focus | 2024 | |
Document Fiscal Period Focus | Q1 | |
Entity Central Index Key | 0001600620 | |
Current Fiscal Year End Date | --12-31 |
CONDENSED CONSOLIDATED BALANCE
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands | Mar. 31, 2024 | Dec. 31, 2023 |
Current assets | ||
Cash, cash equivalents and restricted cash | $ 64,459 | $ 48,875 |
Short-term investments | 255,453 | 301,614 |
Accounts receivable, net | 28,909 | 24,089 |
Inventories, net | 39,761 | 39,705 |
Prepaid expenses | 7,646 | 9,486 |
Other current assets | 1,995 | 1,031 |
Total current assets | 398,223 | 424,800 |
Non-current assets | ||
Long-term investments | 199 | 201 |
Other non-current assets | 1,502 | 1,517 |
Property and equipment, net | 3,198 | 3,354 |
Acquired intellectual property and other intangible assets, net | 4,760 | 4,977 |
Finance right-of-use asset, net | 104,358 | 108,715 |
Operating right-of-use assets, net | 4,394 | 4,498 |
Total assets | 516,634 | 548,062 |
Current liabilities | ||
Accounts payable and accrued liabilities | 50,270 | 54,389 |
Deferred revenue | 4,909 | 4,813 |
Other current liabilities (of which $0.8 million in 2024 and 2023 is due to a related party, respectively) | 1,150 | 2,388 |
Finance lease liability | 13,724 | 14,609 |
Operating lease liabilities | 999 | 989 |
Total current liabilities | 71,052 | 77,188 |
Non-current liabilities | ||
Finance lease liability | 67,475 | 75,479 |
Operating lease liabilities | 6,339 | 6,530 |
Deferred compensation and other non-current liabilities (of which $8.8 million in 2024 and $7.6 million in 2023 is due to a related party, respectively) | 12,292 | 10,911 |
Total liabilities | 157,158 | 170,108 |
Commitments and contingencies (Note 18) | ||
SHAREHOLDER’S EQUITY | ||
Common shares - no par value, unlimited shares authorized, 143,690 and 143,833 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively | 1,207,982 | 1,200,218 |
Additional paid-in capital | 105,419 | 120,788 |
Accumulated other comprehensive loss | (854) | (730) |
Accumulated deficit | (953,071) | (942,322) |
Total shareholders' equity | 359,476 | 377,954 |
Total liabilities and shareholders' equity | $ 516,634 | $ 548,062 |
CONDENSED CONSOLIDATED BALANC_2
CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($) shares in Thousands, $ in Thousands | Mar. 31, 2024 | Dec. 31, 2023 |
Other current liabilities (of which $0.8 million in 2024 and 2023 is due to a related party, respectively) | $ 1,150 | $ 2,388 |
Deferred compensation and other non-current liabilities (of which $8.8 million in 2024 and $7.6 million in 2023 is due to a related party, respectively) | $ 12,292 | $ 10,911 |
Common stock, par value (in usd per share) | $ 0 | $ 0 |
Common stock, issued (in shares) | 143,690 | 143,833 |
Common stock, outstanding (in shares) | 143,690 | 143,833 |
Related Party | ||
Other current liabilities (of which $0.8 million in 2024 and 2023 is due to a related party, respectively) | $ 800 | $ 800 |
Deferred compensation and other non-current liabilities (of which $8.8 million in 2024 and $7.6 million in 2023 is due to a related party, respectively) | $ 8,800 | $ 7,600 |
CONDENSED CONSOLIDATED STATEMEN
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($) shares in Thousands, $ in Thousands | 3 Months Ended | |
Mar. 31, 2024 | Mar. 31, 2023 | |
Revenue | ||
Total revenue, net | $ 50,303 | $ 34,409 |
Operating expenses | ||
Cost of sales | 7,752 | 421 |
Selling, general and administrative | 47,695 | 50,124 |
Research and development | 5,551 | 13,158 |
Restructuring expenses | 6,683 | 0 |
Other (income) expense, net | (4,125) | 290 |
Total cost of sales and operating expenses | 63,556 | 63,993 |
Loss from operations | (13,253) | (29,584) |
Interest expense | (1,283) | 0 |
Interest income | 4,526 | 3,814 |
Net loss before income taxes | (10,010) | (25,770) |
Income tax expense | 739 | 436 |
Net loss | (10,749) | (26,206) |
Other comprehensive (loss) gain: | ||
Unrealized (loss) gain on available-for-sale securities, net of tax of nil | (124) | 73 |
Comprehensive loss | $ (10,873) | $ (26,133) |
Basic loss per share (in usd per share) | $ (0.07) | $ (0.18) |
Diluted loss per share (in usd per share) | $ (0.07) | $ (0.18) |
Weighted-average common shares outstanding used in computation of basic loss per share (in shares) | 144,013 | 142,641 |
Weighted-average common shares outstanding used in computation of diluted loss per share (in shares) | 144,013 | 142,641 |
Product revenue, net | ||
Revenue | ||
Total revenue, net | $ 48,073 | $ 34,337 |
License, collaboration and royalty revenue | ||
Revenue | ||
Total revenue, net | $ 2,230 | $ 72 |
CONDENSED CONSOLIDATED STATEM_2
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Parenthetical) - USD ($) | 3 Months Ended | |
Mar. 31, 2024 | Mar. 31, 2023 | |
Income Statement [Abstract] | ||
Unrealized gain (loss) on available-for-sale securities, net of tax | $ 0 | $ 0 |
CONDENSED CONSOLIDATED STATEM_3
CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY - USD ($) shares in Thousands, $ in Thousands | Total | Common Shares | Additional paid in capital | Accumulated Other Comprehensive (Loss) Income | Accumulated Deficit |
Balance (in shares) at Dec. 31, 2022 | 142,268 | ||||
Balance at Dec. 31, 2022 | $ 405,435 | $ 1,185,309 | $ 85,489 | $ (1,061) | $ (864,302) |
Increase (Decrease) in Stockholders' Equity | |||||
Shares issued on exercise of stock options and vesting of restricted stock units (in shares) | 761 | ||||
Shares issued on exercise of stock options and vesting of restricted stock units | 1,639 | $ 7,710 | (6,071) | ||
Share-based compensation | 9,467 | 9,467 | |||
Unrealized loss on available-for-sale securities, net | 73 | 73 | |||
Net loss | (26,206) | (26,206) | |||
Balance (in shares) at Mar. 31, 2023 | 143,029 | ||||
Balance at Mar. 31, 2023 | $ 390,408 | $ 1,193,019 | 88,885 | (988) | (890,508) |
Balance (in shares) at Dec. 31, 2023 | 143,833 | 143,833 | |||
Balance at Dec. 31, 2023 | $ 377,954 | $ 1,200,218 | 120,788 | (730) | (942,322) |
Increase (Decrease) in Stockholders' Equity | |||||
Shares issued on exercise of stock options and vesting of restricted stock units (in shares) | 6 | 2,231 | |||
Shares issued on exercise of stock options and vesting of restricted stock units | $ 28 | $ 21,134 | (21,106) | ||
Shares repurchased and cancelled, inclusive of transaction costs (in shares) | (2,374) | ||||
Shares repurchased and cancelled, inclusive of transaction costs | (13,370) | $ (13,370) | |||
Share-based compensation | 5,737 | 5,737 | |||
Unrealized loss on available-for-sale securities, net | (124) | (124) | |||
Net loss | $ (10,749) | (10,749) | |||
Balance (in shares) at Mar. 31, 2024 | 143,690 | 143,690 | |||
Balance at Mar. 31, 2024 | $ 359,476 | $ 1,207,982 | $ 105,419 | $ (854) | $ (953,071) |
CONDENSED CONSOLIDATED STATEM_4
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands | 3 Months Ended | |
Mar. 31, 2024 | Mar. 31, 2023 | |
Cash flows used in operating activities: | ||
Net loss | $ (10,749) | $ (26,206) |
Adjustments to reconcile net loss to net cash used in operating activities | ||
Depreciation and amortization | 4,847 | 717 |
Net amortization of premiums and discounts on short-term investments | (3,206) | (2,611) |
Share-based compensation expense | 5,737 | 9,467 |
Foreign exchange on finance lease liability | (6,025) | 0 |
Other, net | 1,559 | 217 |
Net changes in operating assets and liabilities | ||
Accounts receivable, net | (4,820) | (5,559) |
Inventories, net | (56) | (6,993) |
Prepaid expenses and other current assets | 873 | 3,588 |
Non-current operating assets | 17 | (17) |
Accounts payable, accrued and other liabilities | (6,594) | (4,117) |
Operating lease liabilities | (181) | (156) |
Net cash used in operating activities | (18,598) | (31,670) |
Cash flows used in investing activities: | ||
Purchase of investments | (121,260) | (142,397) |
Proceeds from investments | 170,505 | 167,766 |
Purchase of property and equipment | 0 | (347) |
Capitalized patent costs | (12) | (162) |
Net cash provided by investing activities | 49,233 | 24,860 |
Cash flows from financing activities | ||
Repurchase of common shares, net of transaction costs | (12,301) | 0 |
Finance lease payments | (2,778) | 0 |
Proceeds from exercise of stock options | 28 | 1,639 |
Cash (used in) provided by financing activities | (15,051) | 1,639 |
Net increase (decrease) in cash, cash equivalents and restricted cash | 15,584 | (5,171) |
Cash, cash equivalents and restricted cash, beginning of period | 48,875 | 94,172 |
Cash, cash equivalents and restricted cash, end of period | 64,459 | 89,001 |
Supplemental cash flow information | ||
Cash received for interest | 861 | 1,595 |
Cash paid for income taxes | 0 | (1) |
Reconciliation of cash, cash equivalents and restricted cash to the condensed consolidated balance sheets | ||
Cash, cash equivalents | 63,914 | 88,327 |
Restricted cash | 545 | 674 |
Total cash, cash equivalents and restricted cash | $ 64,459 | $ 89,001 |
Organization and Description of
Organization and Description of Business | 3 Months Ended |
Mar. 31, 2024 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
Organization and Description of Business | Organization and Description of Business Aurinia Pharmaceuticals Inc. (Aurinia or the Company) is a fully integrated biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. In January 2021, the Company introduced LUPKYNIS ® (voclosporin), the first U.S. Food and Drug Administration (FDA) approved oral therapy for the treatment of adult patients with active lupus nephritis (LN) and continues to conduct clinical and regulatory activities to support the LUPKYNIS development program. Aurinia contracted with Otsuka Pharmaceutical Co., Ltd. (Otsuka) as a collaboration partner for development and commercialization of LUPKYNIS in the European Union (EU), Japan, as well as the United Kingdom, Russia, Switzerland, Norway, Belarus, Iceland, Liechtenstein and Ukraine (collectively, the Otsuka Territories). On February 15, 2024, the Company announced the conclusion of its strategic review process and actions designed to enhance shareholder value, including an exclusive focus on driving the commercial execution of the LUPKYNIS (voclosporin) business. Aurinia executed a corporate restructuring in the first quarter that reduced employee headcount by approximately 25%. The Company discontinued its AUR300 research and development program and is exploring alternative approaches for AUR200. The corporate restructuring involved the Company reaffirming its commitment to LUPKYNIS growth, while maintaining a sharp focus on operating efficiencies and maximizing cash flows. For further discussion, refer to Note 19, Restructuring. Aurinia's head office and registered office is located at #140, 14315-118 Avenue, Edmonton, Alberta, Canada T5L 4S6. Aurinia also has a U.S. commercial office located at 77 Upper Rock Circle Suite 700, Rockville, Maryland, 20850 United States. Aurinia is incorporated pursuant to the Business Corporations Act (Alberta). The Company’s common shares are traded on the Nasdaq Global Market (Nasdaq) under the symbol AUPH. |
Summary of Significant Accounti
Summary of Significant Accounting Policies | 3 Months Ended |
Mar. 31, 2024 | |
Accounting Policies [Abstract] | |
Summary of Significant Accounting Policies | Summary of Significant Accounting Policies Basis of Presentation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States (U.S. GAAP) for interim financial information and in accordance with the instructions to Form 10-Q and Article 10 of Regulation S-X. In the opinion of management, the accompanying unaudited condensed consolidated financial statements include all adjustments, consisting of normal recurring adjustments considered necessary for fair presentation in accordance with U.S. GAAP. The condensed consolidated balance sheet as of March 31, 2024 was derived from audited annual consolidated financial statements but does not include all annual disclosures required by U.S. GAAP. These condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements included in the Company's Annual Report on Form 10-K for the year ended December 31, 2023. The results of operations for the three months ended March 31, 2024 are not necessarily indicative of the results to be expected for the full year or any other future periods. These unaudited condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries, Aurinia Pharma U.S., Inc. (Delaware incorporated) and Aurinia Pharma Limited (UK incorporated). All intercompany balances and transactions have been eliminated in consolidation and operate in one segment. These unaudited condensed consolidated financial statements are presented in U.S. dollars, which is the Company's and all of its foreign subsidiaries' functional currency. Therefore, there is no currency translation adjustment upon consolidation as the remeasurement of gains or losses are recorded in the condensed consolidated statements of operations. All monetary assets and liabilities denominated in a foreign currency are remeasured into U.S. dollars at the exchange rate on the balance sheet date. Non-monetary assets and liabilities (along with their related expenses) are translated at the rate of exchange in effect on the date assets were acquired. Monetary income and expense items are translated at the average foreign currency rate. Foreign exchange gains and losses arising on translation or settlement of a foreign currency denominated monetary item are included in the consolidated statements of operations and recorded in other (income) expense, net. Significant Accounting Policies The Company's significant accounting policies have not changed from those previously described in the Company's Annual Report on Form 10-K for the year ended December 31, 2023. Product Revenues We sell LUPKYNIS (voclosporin) primarily to specialty pharmacies and specialty distributors and directly to our ex-U.S. partner Otsuka. These customers subsequently distribute the Company's products to patients and healthcare providers. Revenues from product sales are recognized when the customer obtains control of the Company's product, which typically occurs upon delivery to the customer. Reserves for discounts and allowances: Product sales are recorded at the net sales price, which includes estimates of variable consideration for which reserves are established. These reserves are based on estimates of the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable (if the amount is payable to the customer) or a liability (if the amount is payable to a party other than the customer). The Company's estimates of reserves established for variable consideration are calculated based upon utilizing the expected value method. The transaction price, which includes variable consideration reflecting the impact of discounts and allowances, may be subject to constraint and is included in the net sales price only to the extent that it is probable that a significant reversal of the amount of the cumulative revenues recognized will not occur in a future period. Amounts related to such items are estimated at contract inception and updated at the end of each reporting period as additional information becomes available. Significant judgment is required in estimating variable consideration. In making these estimates, the Company considers historical data, including patient mix and inventory sold to customers that has not yet been dispensed. The Company uses a data aggregator and historical claims to estimate variable consideration for inventory sold to customers, including specialty pharmacies and specialty distributors, that has not yet been dispensed to patients. Actual amounts may ultimately differ from the Company's estimates. If actual results vary, the Company adjusts these estimates, which could have an effect on earnings in the period of adjustment. As of March 31, 2024, the Company did not have any material adjustments to variable consideration estimates based on actual results. These specific adjustments are detailed further in the Company's Annual Report on Form 10-K for the year ended December 31, 2023. Major Customers: The Company currently has two main specialty pharmacies for U.S. commercial sales of LUPKYNIS and a collaboration partnership with Otsuka for sales of semi-finished product and royalty, collaboration and manufacturing services revenue in the Otsuka Territories. The percentages of total revenues, net from our main customers were as follows: Three months ended March 31, 2024 2023 Two main specialty pharmacies 91% 99% Collaboration partnership 7% —% In late March 2022, the Company provided a nominal additional discount to both of its two main U.S. specialty pharmacies, applicable for the 2022 calendar year, in connection with holding additional amounts of LUPKYNIS on hand due to supply chain concerns. In December 2022, the Company extended the nominal discount to the end of 2024. Such discounts, or any future discounts, may result in reduced sales to these customers in subsequent periods and substantial fluctuations in revenues from period to period. The Company monitors economic conditions, the creditworthiness of customers and government regulations and funding, both domestically and abroad. The Company regularly communicates with its customers regarding the status of receivable balances. Global economic conditions and customer specific factors may require the Company to periodically reevaluate the collectability of its receivables and based on this evaluation the Company could potentially incur credit losses. The Company has had no historical write-offs related to customers or receivables. Accounts Receivable, net: Accounts receivable are stated at their net realizable value. The Company's accounts receivable primarily represent amounts due to the Company from product sales and from its Otsuka collaboration agreement (Note 12). As of March 31, 2024 and December 31, 2023, accounts receivable, net are $28.9 million and $24.1 million, respectively. The Company's standard credit terms range from 30 to 45 days. The Company does not assess whether a contract has a significant financing component if the expectation at contract inception is such that the period between the transfer of the promised good to the customer and receipt of payment will be one year or less. The Company estimates the allowances using the current expected credit loss, or CECL, model. Under the CECL model, the allowances reflect the net amount expected to be collected from the account receivables. Aurinia evaluates the collectability of these cash flows based on the asset’s amortized cost, the risk of loss even when that risk is remote, losses over an asset’s contractual life, and other relevant information available to the Company. Accounts receivable balances are written off against the allowance when it is probable that the receivable will not be collected. Given the nature of the Company's accounts receivable, it determined that an allowance for current expected credit losses was nil as of March 31, 2024 and December 31, 2023. Share-Based Compensation: The Company follows ASC Topic 718, Compensation - Stock Compensation (ASC 718), which requires the measurement and recognition of compensation expense, based on estimated fair values, for all share-based awards made to employees and directors. The Company records compensation expense based on the fair value on the grant date using the graded accelerated vesting method for all share-based payments related to stock options, performance awards (PAs), restricted stock units (RSUs) and purchases under the Company's 2021 Employee Share Purchase Plan (ESPP). The estimated fair value of performance-based awards is measured on the grant date and is recognized when it is determined that it is probable that the performance condition will be achieved. The Company has elected a policy for all share-based awards to estimate forfeitures based on historical forfeiture experience at the time of grant and revise in subsequent periods if actual forfeitures differ from those estimates. Restructuring Expenses: Restructuring expense consists primarily of employee severance, contract termination costs and other costs. Liabilities for costs associated with a restructuring activity are recognized when the liability is incurred and are measured at fair value. According to ASC 420, Exit or Disposal Cost Obligations , one-time employee severance and termination benefits are expensed at the date the entity notifies the employee of the plan, unless the employee must provide future service, in which case the benefits are expensed in the period when the service ends. One-time termination benefits include severance, continuation of health insurance coverage for certain employees, and other benefits such as outplacement support services for a specified period of time. Common Shares: The Company’s shares have no par value or stated value and therefore, upon repurchase or issuance of shares, all amounts related to the shares are recorded under common shares on the balance sheet. The value of common shares includes cash amounts paid or received for the shares and the fair value of equity awards and warrants. Amounts for common shares are offset by share issue costs or transactions costs associated with repurchases or equity offerings. Recent Accounting Pronouncements In December 2023, the FASB issued final guidance in ASU No. 2023-09, Income Taxes (ASC 740): Improvements to Income Tax Disclosures requiring entities to provide additional information in the rate reconciliation and disclosures about income taxes paid. For public business entities, the guidance is effective for annual periods beginning after December 15, 2024. The Company is not early adopting, and therefore, this ASU is not adopted in the current period. The Company does not expect this ASU to have a material impact on the consolidated financial statements. In November 2023, the FASB issued ASU No. 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures which requires public entities to disclose significant segment expenses regularly provided to the chief operating decision-maker. Public entities with a single reporting segment have to provide all disclosures required by ASC 280, including the significant segment expense disclosures. For public business entities, the guidance is effective for annual periods beginning after December 15, 2023. This ASU does not have a material impact on the consolidated financial statements. |
Fair Value Measurements
Fair Value Measurements | 3 Months Ended |
Mar. 31, 2024 | |
Fair Value Disclosures [Abstract] | |
Fair Value Measurements | Fair Value Measurements The Company's financial instruments consist primarily of cash and cash equivalents, investments, accounts receivable, accounts payable and accrued liabilities. The carrying value of accounts receivable, accounts payable and accrued liabilities approximate their fair value because of their short-term nature. Estimated fair value of available-for-sale debt securities are generally based on prices obtained from commercial pricing services. In connection with measuring the fair value of its assets and liabilities, the Company seeks to maximize the use of observable inputs (market data obtained from sources independent from the Company) and to minimize the use of unobservable inputs (the Company’s assumptions about how market participants would price assets and liabilities). As a basis for considering such assumptions, a three-tier fair value hierarchy has been established, which prioritizes the inputs used in measuring fair value as follows: • Level 1 - Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities. • Level 2 - Inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active. • Level 3 - Unobservable inputs that reflect the reporting entity’s own assumptions. The following table summarizes the financial assets (cash, cash equivalents, restricted cash and investments) measured at fair value on a recurring basis: March 31, 2024 (in thousands) Level 1 Level 2 Level 3 Total Financial assets: Cash, cash equivalents and restricted cash $ 64,459 $ — $ — $ 64,459 Corporate bonds — 23,745 — 23,745 Commercial paper — 38,243 — 38,243 Treasury bills — 134,974 — 134,974 Treasury bonds — 58,690 — 58,690 Total financial assets $ 64,459 $ 255,652 $ — $ 320,111 December 31, 2023 (in thousands) Level 1 Level 2 Level 3 Total Financial assets: Cash, cash equivalents and restricted cash $ 48,875 $ — $ — $ 48,875 Corporate bonds — 33,781 — 33,781 Commercial paper — 39,304 — 39,304 Treasury bills — 122,806 — 122,806 Treasury bonds — 105,924 — 105,924 Total financial assets $ 48,875 $ 301,815 $ — $ 350,690 The Company's Level 1 instruments include cash, cash equivalents and restricted cash that are valued using quoted market prices. Aurinia estimates the fair values of investments in corporate debt securities, government and government related securities and certificates of deposits by taking into consideration valuations obtained from third-party pricing services. The fair value of the Company's investments classified within Level 2 is based upon observable inputs that may include benchmark yield curves, reported trades, issuer spreads, benchmark securities and reference data including market research publications. At March 31, 2024 and December 31, 2023, the weighted average remaining contractual maturities of Aurinia's Level 2 investments were approximately 6 months and 7 months, respectively. It is the Company's policy for these investments to have an overall rating of A-1, or higher, by Standard & Poor's, or an equivalent rating by Moody’s or Fitch. No credit loss allowance was recorded as of March 31, 2024 and December 31, 2023, as the Company does not believe the unrealized loss is a result of a credit loss due to the nature of the investments. Aurinia also considered the current and expected future economic and market conditions and determined that the estimate of credit losses was not significantly impacted. Refer to Note 4, Cash, Cash Equivalents, Restricted Cash and Investments , for the carrying amount and related unrealized gains (losses) by type of investment. |
Cash, Cash Equivalents, Restric
Cash, Cash Equivalents, Restricted Cash and Investments | 3 Months Ended |
Mar. 31, 2024 | |
Investments, Debt and Equity Securities [Abstract] | |
Cash, Cash Equivalents, Restricted Cash and Investments | Cash, Cash Equivalents, Restricted Cash and Investments As of March 31, 2024 and December 31, 2023, the Company had $320.1 million and $350.7 million, respectively of cash, cash equivalents, restricted cash and investments summarized below. As of March 31, 2024 and December 31, 2023, $255.7 million and $301.8 million were available-for-sale debt securities which are carried at fair market value. March 31, 2024 (in thousands) Amortized Cost Unrealized Gains Unrealized Losses Estimated Fair Value Cash, cash equivalents and restricted cash $ 64,459 $ — $ — $ 64,459 Corporate bonds 23,547 — (3) 23,544 Commercial paper 38,273 — (30) 38,243 Treasury bills 134,984 — (9) 134,975 Treasury bonds 58,697 — (7) 58,690 Total cash, cash equivalents, restricted cash and short-term investments 319,960 — (49) 319,911 Total long-term investment corporate bond 199 1 — 200 Total cash, cash equivalents, restricted cash and investments $ 320,159 $ 1 $ (49) $ 320,111 December 31, 2023 (in thousands) Amortized Cost Unrealized Gains Unrealized Losses Estimated Fair Value Cash, cash equivalents and restricted cash $ 48,875 $ — $ — $ 48,875 Corporate bonds 33,576 4 — 33,580 Commercial paper 39,305 — (1) 39,304 Treasury bills 122,757 49 — 122,806 Treasury bonds 105,903 21 — 105,924 Total cash, cash equivalents, restricted cash and short-term investments 350,416 74 (1) 350,489 Total long-term investment corporate bond 200 1 — 201 Total cash, cash equivalents, restricted cash and investments $ 350,616 $ 75 $ (1) $ 350,690 As of March 31, 2024 and December 31, 2023, accrued interest receivable from investments was $1.0 million and $0.7 million, respectively. During the three months ended March 31, 2024 and 2023, the Company had $(124) thousand and $73 thousand of unrealized losses and gains on available-for-sale securities, net of tax, respectively, which are included as a component of comprehensive loss on the consolidated statements of operations. Currently, the Company does not intend to sell investments that are in an unrealized loss position, and it is unlikely the Company will be required to sell the investments before recovery of their amortized cost basis, which may be at maturity. The Company has determined that the gross unrealized losses on investments at March 31, 2024, were temporary in nature. Realized gains or losses were immaterial during the three months ended March 31, 2024 and 2023. |
Inventories, net
Inventories, net | 3 Months Ended |
Mar. 31, 2024 | |
Inventory Disclosure [Abstract] | |
Inventories, net | Inventories, net Inventories are valued under a standard costing methodology on a first-in, first-out basis and are stated at the lower of cost or net realizable value. The Company capitalizes inventory costs related to products to be sold in the ordinary course of business. The Company makes a determination of capitalizing inventory costs for a product based on, among other factors, status of regulatory approval, information regarding safety, efficacy and expectations relating to commercial sales and recoverability of costs. Capitalized costs of inventories for LUPKYNIS (voclosporin) mainly include third party manufacturing costs, transportation, storage, insurance, and allocated internal labor. Due to the nature of the Company's supply chain process, inventory that is owned by the Company, is physically stored at third-party warehouses, logistics providers, and contract manufacturers. The Company assesses recoverability of inventory each reporting period to determine any write-down to net realizable value resulting from excess or obsolete inventories. As of March 31, 2024 and December 31, 2023, Aurinia recorded reserves of finished goods inventories of approximately $0.5 million and $0.8 million, respectively, which were primarily related to potential inventory obsolescence. The components of inventory, net are as follows: (in thousands) March 31, 2024 December 31, 2023 Raw materials $ 1,702 $ 1,746 Work in process 35,994 37,376 Finished goods, net of reserve 2,065 583 Total inventories, net $ 39,761 $ 39,705 |
Prepaid Expenses
Prepaid Expenses | 3 Months Ended |
Mar. 31, 2024 | |
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract] | |
Prepaid Expenses | Prepaid Expenses Prepaid expenses are as follows: (in thousands) March 31, 2024 December 31, 2023 Prepaid assets $ 4,707 $ 6,892 Prepaid deposits 2,376 1,345 Prepaid insurance 563 1,249 Total prepaid expenses $ 7,646 $ 9,486 |
Intangible Assets
Intangible Assets | 3 Months Ended |
Mar. 31, 2024 | |
Goodwill and Intangible Assets Disclosure [Abstract] | |
Intangible Assets | Intangible Assets The following table summarizes the carrying amount of intangible assets, net of accumulated amortization. March 31, 2024 (in thousands) Gross Carrying Accumulated Net Carrying Patents $ 1,860 $ (1,307) $ 553 Acquired intellectual property and reacquired rights 15,126 (10,937) 4,189 Internal-use software implementation costs 2,873 (2,855) 18 $ 19,859 $ (15,099) $ 4,760 December 31, 2023 (in thousands) Gross Carrying Accumulated Net Carrying Patents $ 1,847 $ (1,297) $ 550 Acquired intellectual property and reacquired rights 15,126 (10,737) 4,389 Internal-use software implementation costs 2,873 (2,835) 38 $ 19,846 $ (14,869) $ 4,977 Amortization expense for the three months ended March 31, 2024 and 2023 was approximately $0.2 million and $0.5 million, respectively. |
Property and Equipment, net
Property and Equipment, net | 3 Months Ended |
Mar. 31, 2024 | |
Property, Plant and Equipment [Abstract] | |
Property and Equipment, net | Property and Equipment, net Property and equipment, net are as follows: (in thousands) March 31, 2024 December 31, 2023 Leasehold improvements $ 3,243 $ 3,243 Office equipment 631 631 Furniture 1,155 1,155 Computer equipment 235 235 5,264 5,264 Less accumulated depreciation (2,066) (1,910) Property and equipment, net $ 3,198 $ 3,354 |
Lease Obligations
Lease Obligations | 3 Months Ended |
Mar. 31, 2024 | |
Leases [Abstract] | |
Lease Obligations | Lease Obligations The Company has the following lease obligations: Victoria, British Columbia In December 2020, Aurinia entered into a lease for office space in Victoria, British Columbia. During September 2022, the fixed lease term ended on the Victoria lease and the Company exercised its right to enter into a short-term month to month lease, of which expenses are incurred in SG&A. On March 31, 2023, the Company terminated the Victoria lease. Rockville, Maryland During March 2020, the Company entered into a lease for its U.S. commercial office in Rockville, Maryland for a total of 30,531 square feet of office space. The lease has a remaining term of approximately seven years and has an option to extend for two five-year periods after the initial term of 11 years has elapsed and has an option to terminate after seven years. As of March 31, 2024, the Company had a right-of-use (ROU) asset of $4.4 million and lease liability of $7.2 million included in the condensed consolidated balance sheets. As of December 31, 2023, the Company had a right of use asset of $4.5 million and lease liability of $7.4 million included in the condensed consolidated balance sheets. The Company recorded leasehold improvement incentives in the amount of $2.3 million as additions to the lease liability. The lease term commenced on March 12, 2020. When measuring the lease liability, the Company discounted lease payments using its incremental borrowing rate at March 12, 2020. The incremental borrowing rate applied to the lease liability on March 12, 2020 was 5.2% based on the financial position of the Company, geographical region and term of lease. Edmonton, Alberta During October 2022, the Company entered into a long term lease in Edmonton for a total of 4,375 square feet of office space. The lease is a six year lease and has an option to renew after five years at prevailing market rates. The lease commenced on November 1, 2022 and the Company recorded the lease as an operating lease. The lease is not material to the Company's financial position. For all leases, the Company incurs variable lease costs. These costs include operation and maintenance costs included in SG&A and are expensed as incurred. The variable lease costs are not material to the Company's financial position. The operating lease costs for all leases for the three months ended March 31, 2024 and March 31, 2023 were $0.2 million for both periods. Monoplant The Company, at lease inception, recorded an ROU asset of approximately $117.6 million and a corresponding lease liability of $94.1 million, which is the present value of the minimum lease payments beginning July 2023 and expiring in 2030. The incremental borrowing rate applied to value the lease liability at inception is 6.19%, which was based on the financial position of the Company, geographical region and term of lease. As of March 31, 2024, the ROU asset, net and corresponding lease liability balance were $104.4 million and $81.2 million, respectively. As of December 31, 2023, the ROU asset, net and corresponding lease liability balance were $108.7 million and $90.1 million, respectively. For the three months ended March 31, 2024, ROU amortization was $4.4 million and interest expense was $1.3 million. The following table represents the weighted-average remaining lease terms and discount rates as of March 31, 2024: As of March 31, 2024 Weighted Average Remaining Lease Term (years) Weighted Average Discount Rate Operating leases 7.4 5.28% Finance lease 6.0 6.19% Supplemental cash flow information related to leases are as follows: Three months ended 2024 2023 (in thousands) Cash paid for amounts included in the measurement of lease liabilities Financing cash flows from finance lease $ (2,778) $ — Operating cash flows from finance lease $ (1,370) $ — Operating cash flows from operating leases $ (276) $ (263) Supplemental disclosure of noncash transactions Finance right-of-use asset obtained in exchange for lease obligations (monoplant) $ 104,359 $ — Finance lease liability arising from obtaining right-of-use assets (monoplant) $ 81,199 $ — Future maturities of lease liabilities as of March 31, 2024 are as follows: (in thousands) Finance Lease Payments Operating Lease Payments Remainder of 2024 $ 12,052 $ 838 2025 16,070 1,141 2026 16,070 1,169 2027 16,070 1,198 2028 16,070 1,227 Thereafter 20,087 3,303 Total lease payments 96,419 8,876 Less: imputed interest (15,220) (1,538) Total $ 81,199 $ 7,338 Beinheim |
Accounts Payable and Accrued Li
Accounts Payable and Accrued Liabilities | 3 Months Ended |
Mar. 31, 2024 | |
Payables and Accruals [Abstract] | |
Accounts Payable and Accrued Liabilities | Accounts Payable and Accrued Liabilities Accounts payable and accrued liabilities are as follows: (in thousands) March 31, 2024 December 31, 2023 Employee accruals $ 11,412 $ 22,486 Commercial accruals 20,078 16,216 Accrued R&D projects 2,665 5,503 Trade payables 5,672 4,327 Restructuring accruals 2,070 — Other accrued liabilities 6,965 5,190 Income taxes payable 1,408 667 Total accounts payable and accrued liabilities $ 50,270 $ 54,389 As of March 31, 2024, liabilities related to restructuring costs of $2.1 million are included within accounts payable and accrued liabilities on the condensed consolidated balance sheets. Restructuring accruals primarily include employee severance and contract termination expenses. |
Deferred Compensation and Other
Deferred Compensation and Other Non-current Liabilities | 3 Months Ended |
Mar. 31, 2024 | |
Payables and Accruals [Abstract] | |
Deferred Compensation and Other Non-current Liabilities | Deferred Compensation and Other Non-current Liabilities The Company recorded other non-current liabilities of $12.3 million and $10.9 million as of March 31, 2024 and December 31, 2023, respectively. The balance as of March 31, 2024 and December 31, 2023 primarily included deferred compensation arrangements whereby certain former executive officers as of March 8, 2012 were provided with future potential employee benefit obligations for remaining with the Company for a certain period of time. These obligations were also contingent on the occurrence of uncertain future events. One of the former officers, Dr. Robert T. Foster, is considered a related party following his appointment to the Board of Directors on September 21, 2023. For further discussion, refer to Note 17, Related Party Transactions. |
License and Collaboration Agree
License and Collaboration Agreements | 3 Months Ended |
Mar. 31, 2024 | |
Revenue from Contract with Customer [Abstract] | |
License and Collaboration Agreements | License and Collaboration Agreements Otsuka Contract On December 17, 2020, the Company entered into a collaboration and license agreement with Otsuka for the development and commercialization of oral LUPKYNIS in the Otsuka Territories. For full description of the agreements the Company has entered into with Otsuka, please refer to the Annual Report on Form 10-K for the year ended December 31, 2023. As part of the agreement, the Company received an upfront cash payment of $50.0 million in 2020 for the license agreement and has received $40.0 million in regulatory and pricing approval related milestones. The Company provides semi-finished product of LUPKYNIS to Otsuka on a cost-plus basis, sharing capacity of the monoplant and receives tiered royalties ranging from 10 to 20 percent (dependent on territory and achievement of sale thresholds) on net product sales by Otsuka, along with additional milestone payments based on the attainment of certain annual sales. In addition, certain collaboration services are to be provided to Otsuka on agreed upon rates. On November 13, 2023, Otsuka filed a new drug application (NDA) for voclosporin for the treatment of lupus nephritis (LN) with the Japanese Ministry of Health, Labour, and Welfare for the manufacture and sale in Japan of voclosporin. The Company is eligible to receive a payment of $10 million upon approval in Japan, which is anticipated in the second half of 2024, along with low double-digit royalties on net sales once launched. For the three months ended March 31, 2024 and March 31, 2023, the Company recognized $2.2 million and $0.1 million, respectively of license, collaboration and royalty revenue from services provided under the Otsuka agreement. Riptide License On August 17, 2021, AUR300 (M2 macrophage modulation via CD206 binding) was secured through a global licensing and research agreement with Riptide Bioscience, Inc. (Riptide), a private company. Effective February 14, 2024 the Company is ceasing future development of AUR300. |
Shareholder's Equity
Shareholder's Equity | 3 Months Ended |
Mar. 31, 2024 | |
Equity [Abstract] | |
Shareholder's Equity | Shareholder's Equity On February 15, 2024, Aurinia announced that its Board of Directors had approved a share repurchase program of up to $150 million of common shares of the Company, affirming its confidence in the Company's growth prospects. On February 29, 2024, Canadian securities regulators granted exemptive relief for the Company’s share repurchase program, authorizing the Company to purchase up to 15 percent of its issued and outstanding shares in any 12-month period for up to 36 months, including under the current program. This program may be implemented through open market or privately negotiated purchases, including under a plan intended to comply with the affirmative defense under Rule 10b5-1, Rule 10b-18 or an automatic securities purchase plan, an accelerated share repurchase program, or other mechanisms. The timing and amount of repurchase transactions will be determined by management based on its evaluation of market conditions, share price, legal requirements, including applicable blackout period restrictions, and other factors. The purchase price of any Common Shares will be determined in accordance with applicable U.S. securities laws and subject to receiving the Exemptive Relief, the value of the consideration offered per Common Share will not exceed the market price of the Common Shares calculated pursuant to applicable Canadian securities regulation. As of March 31, 2024, the Company had repurchased approximately 2.4 million of Aurinia's common shares for $13.4 million (including transaction costs which consist of commissions and excise tax). The cost of repurchased shares are reported as a reduction in common stock and under Alberta law, the shares were cancelled and not reissued. |
Net Loss per Common Share
Net Loss per Common Share | 3 Months Ended |
Mar. 31, 2024 | |
Earnings Per Share [Abstract] | |
Net Loss per Common Share | Net Loss per Common Share Basic and diluted net loss per common share is computed by dividing net loss by the weighted average number of common shares outstanding. Since the Company was in a loss position for all periods presented, diluted net loss per share is the same as basic net loss per share. The numerator and denominator used in the calculation of basic and diluted net loss per common share are as follows: Three months ended March 31, (in thousands, except per share data) 2024 2023 Net loss $ (10,749) $ (26,206) Weighted average common shares outstanding 144,013 142,641 Net loss per common share (expressed in $ per share) $ (0.07) $ (0.18) The Company did not include the securities in the following table in the computation of the net loss per common share because the effect would have been anti-dilutive during each period: Three months ended March 31, (in thousands) 2024 2023 Stock options 11,081 12,678 Unvested performance awards 1,503 921 Unvested restricted stock units 7,326 6,983 19,910 20,582 |
Share-based Compensation
Share-based Compensation | 3 Months Ended |
Mar. 31, 2024 | |
Share-Based Payment Arrangement [Abstract] | |
Share-based Compensation | Share-based Compensation The Company's Amended and Restated Equity Incentive Plan (the Plan), which was adopted and approved by the Company's shareholders in June 2021, allows for an issuance of up to an aggregate of 23.8 million shares (inclusive of then outstanding awards) and provides for grants of stock options, performance awards (PAs), and restricted stock units (RSUs) that may be settled in cash and common shares. Also in June 2021, the Company's shareholders adopted and approved the Company's Employee Stock Purchase Plan (2021 ESPP), which allows for the issuance of up to 2.5 million shares. The 2021 ESPP is intended to qualify as an “employee stock purchase plan” under Section 423 of the Internal Revenue Code but also permits the Company to include the employees, including non-United States employees, in offerings not intended to qualify under Section 423. The purpose of the 2021 ESPP is to provide eligible employees with opportunities to purchase the Company’s common shares at a discounted price. As of March 31, 2024, 0.7 million shares were purchased under the ESPP. In addition to stock options, PAs and RSUs granted under the Plan, the Company has granted certain stock options and RSUs as inducements material to new employees entering employment in accordance with Nasdaq Listing Rule 5635(c)(4). The inducements were granted outside of the Plan. Stock Options The Plan requires the exercise price of each option not to be less than the closing market price of the Company’s common shares on the business day immediately prior to the date of grant. The Board of Directors approves the vesting criteria and periods at its discretion. The options issued under the Plan are accounted for as equity-settled share-based payments. The Company used the Black-Scholes option pricing model to estimate the fair value of the options granted. The assumptions used for the annual volatility and expected life of the options are reviewed and updated annually. The Company considers historical volatility of its common shares in estimating its future stock price volatility. The risk-free interest rate for the expected life of the options was based on the yield available on government benchmark bonds with an approximate equivalent remaining term at the time of the grant. The expected life is based upon the contractual term, taking into account expected employee exercise and expected post-vesting employment termination behavior. The following weighted average assumptions were used to estimate the fair value of the options granted during the three months ended March 31, 2024 and March 31, 2023: 2024 2023 Annualized volatility 77 % 71 % Risk-free interest rate 4.04 % 4.08 % Expected life of options in years 5.0 years 5.0 years Estimated forfeiture rate 13.1 % 12.7 % Dividend rate 0.0 % 0.0% Fair value per common share option $ 4.62 $ 5.44 The following table summarizes the option award activity for the three months ended March 31, 2024: March 31, 2024 Number of shares (in thousands) Weighted average exercise price $ Outstanding - December 31, 2023 11,556 $ 10.63 Granted 63 7.12 Exercised (6) 4.85 Forfeited or cancelled (532) 11.62 Outstanding - March 31, 2024 11,081 $ 10.57 Restricted Stock Units and Performance Awards The Company has granted RSUs and PAs under the Plan, as well as inducements for certain new hires as discussed above. The RSUs and PAs are fair valued based on the previous business days' market price of common shares on the date of the grant. The following table summarizes the RSU and PA activity for the three months ended March 31, 2024: March 31, 2024 Number of shares (in thousands) Weighted average fair value price $ Unvested balance, December 31, 2023 7,807 $ 9.29 Granted 4,491 6.94 Vested (2,225) 9.48 Forfeited (1,244) 9.12 Unvested balance, March 31, 2024 8,829 $ 8.07 Share-based Compensation Expense The Company recognized share-based compensation expense for the three months ended March 31, 2024 and March 31, 2023 as follows: Three months ended (in thousands) 2024 2023 Research and development $ (2,166) $ 1,590 Selling, general and administrative 7,537 7,589 Capitalized under inventories 366 288 Share-based compensation expense $ 5,737 $ 9,467 As of March 31, 2024, there was $40.4 million of unrecognized share-based compensation expense related to unvested awards granted which is expected to be recognized over a weighted-average period of approximately 1.6 years. |
Income Taxes
Income Taxes | 3 Months Ended |
Mar. 31, 2024 | |
Income Tax Disclosure [Abstract] | |
Income Taxes | Income Taxes The effective tax rates for the three months ended March 31, 2024 and March 31, 2023 differed from the federal statutory rate applied to losses before income taxes primarily as a result of the mix of income, losses and valuation allowances. The Company recognized an income tax expense of approximately $739 thousand and $436 thousand for the three months ended March 31, 2024 and March 31, 2023, respectively. The expense recognized for these periods is a result of income in certain jurisdictions. This tax expense was not offset by a tax benefit as the Company had losses that are fully offset by a valuation allowance in its significant jurisdictions. |
Related Party Transactions
Related Party Transactions | 3 Months Ended |
Mar. 31, 2024 | |
Related Party Transactions [Abstract] | |
Related Party Transactions | Related Party Transactions On September 21, 2023, the Company appointed Dr. Robert T. Foster to the Board of Directors. Dr. Foster is considered a related party since he is one of the former executive officers of the Company who, as of March 8, 2012 was provided with future potential employee benefit obligations for remaining with the Company for a certain period of time. These obligations are contingent on the occurrence of uncertain future events. Dr. Foster was not a related party of the Company between his resignation from the Company in 2014, and his appointment to the Board of Directors on September 21, 2023. As of March 31, 2024, the Company had $0.8 million and $8.8 million of current and non-current liabilities related to Dr. Foster, respectively. As of December 31, 2023, the Company had $0.8 million and $7.6 million of current and non-current liabilities related to Dr. Foster, respectively. As of March 31, 2024 and December 31, 2023 the Company had made payments of $0.1 million to him for each period as a related party for the deferred compensation. |
Commitments and Contingencies
Commitments and Contingencies | 3 Months Ended |
Mar. 31, 2024 | |
Commitments and Contingencies Disclosure [Abstract] | |
Commitments and Contingencies | Commitments and Contingencies The Company may, from time to time, be subject to claims and legal proceedings brought against it in the normal course of business. Such matters are subject to many uncertainties. Management believes the ultimate resolution of such contingencies will not have a material adverse effect on the consolidated financial position of the Company. The Company's material commitments and contingencies have not changed in any material manner from those previously described in the Company's Annual Report on Form 10-K for the year ended December 31, 2023. Other Funding Commitments In the normal course of business, the Company enters into agreements with contract research organizations, contract manufacturing organizations and other third parties for services to be provided to the Company. Generally, these agreements provide for termination upon notice, with specified amounts due upon termination based on the timing of termination and the terms of the agreement. The actual amounts and timing of payments under these agreements are uncertain and contingent upon the initiation and completion of services to be provided to the Company. |
Restructuring
Restructuring | 3 Months Ended |
Mar. 31, 2024 | |
Restructuring and Related Activities [Abstract] | |
Restructuring | Restructuring On February 15, 2024, the Company announced the conclusion of its strategic review process and actions designed to enhance shareholder value, including an exclusive focus on driving the commercial execution of the LUPKYNIS (voclosporin) business. Aurinia executed a corporate restructuring in the first quarter that reduced employee headcount by approximately 25%. The Company discontinued its AUR300 research and development program and is exploring alternative approaches for AUR200. The corporate restructuring involved the Company reaffirming its commitment to LUPKYNIS growth ensuring product quality and patient safety, while maintaining a sharp focus on operating efficiencies and maximizing cash flows. The Company also announced it plans to reduce employee headcount by at least 25% by the end of the first quarter of 2024. As of March 31, 2024, the restructuring expenses recorded by the Company were as follows: (in thousands) Three months ended March 31, 2024 Employee severance and one time benefits $ 5,207 Contract terminations 919 Other costs 557 Total $ 6,683 During the first quarter of 2024, restructuring expenses of approximately $6.7 million were recorded in connection with this program and are included within operating expenses on the condensed consolidated statements of operations and comprehensive loss. |
Subsequent Events
Subsequent Events | 3 Months Ended |
Mar. 31, 2024 | |
Subsequent Events [Abstract] | |
Subsequent Events | Subsequent Events From April 1, 2024 through April 30, 2024 the Company has repurchased approximately 1.0 million of additional Aurinia common shares for $5.2 million (including transaction costs). The cost of repurchased shares will be reported as a reduction in common stock and subsequently canceled. |
Summary of Significant Accoun_2
Summary of Significant Accounting Policies (Policies) | 3 Months Ended |
Mar. 31, 2024 | |
Accounting Policies [Abstract] | |
Basis of Presentation | Basis of Presentation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States (U.S. GAAP) for interim financial information and in accordance with the instructions to Form 10-Q and Article 10 of Regulation S-X. In the opinion of management, the accompanying unaudited condensed consolidated financial statements include all adjustments, consisting of normal recurring adjustments considered necessary for fair presentation in accordance with U.S. GAAP. The condensed consolidated balance sheet as of March 31, 2024 was derived from audited annual consolidated financial statements but does not include all annual disclosures required by U.S. GAAP. These condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements included in the Company's Annual Report on Form 10-K for the year ended December 31, 2023. The results of operations for the three months ended March 31, 2024 are not necessarily indicative of the results to be expected for the full year or any other future periods. |
Principles of consolidation | These unaudited condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries, Aurinia Pharma U.S., Inc. (Delaware incorporated) and Aurinia Pharma Limited (UK incorporated). All intercompany balances and transactions have been eliminated in consolidation and operate in one segment. These unaudited condensed consolidated financial statements are presented in U.S. dollars, which is the Company's and all of its foreign subsidiaries' functional currency. Therefore, there is no currency translation adjustment upon consolidation as the remeasurement of gains or losses are recorded in the condensed consolidated statements of operations. All monetary assets and liabilities denominated in a foreign currency are remeasured into U.S. dollars at the exchange rate on the balance sheet date. Non-monetary assets and liabilities (along with their related expenses) are translated at the rate of exchange in effect on the date assets were acquired. Monetary income and expense items are translated at the average foreign currency rate. Foreign exchange gains and losses arising on translation or settlement of a foreign currency denominated monetary item are included in the consolidated statements of operations and recorded in other (income) expense, net. |
Product Revenues | Product Revenues We sell LUPKYNIS (voclosporin) primarily to specialty pharmacies and specialty distributors and directly to our ex-U.S. partner Otsuka. These customers subsequently distribute the Company's products to patients and healthcare providers. Revenues from product sales are recognized when the customer obtains control of the Company's product, which typically occurs upon delivery to the customer. Reserves for discounts and allowances: Product sales are recorded at the net sales price, which includes estimates of variable consideration for which reserves are established. These reserves are based on estimates of the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable (if the amount is payable to the customer) or a liability (if the amount is payable to a party other than the customer). The Company's estimates of reserves established for variable consideration are calculated based upon utilizing the expected value method. The transaction price, which includes variable consideration reflecting the impact of discounts and allowances, may be subject to constraint and is included in the net sales price only to the extent that it is probable that a significant reversal of the amount of the cumulative revenues recognized will not occur in a future period. Amounts related to such items are estimated at contract inception and updated at the end of each reporting period as additional information becomes available. Significant judgment is required in estimating variable consideration. In making these estimates, the Company considers historical data, including patient mix and inventory sold to customers that has not yet been dispensed. The Company uses a data aggregator and historical claims to estimate variable consideration for inventory sold to customers, including specialty pharmacies and specialty distributors, that has not yet been dispensed to patients. Actual amounts may ultimately differ from the Company's estimates. If actual results vary, the Company adjusts these estimates, which could have an effect on earnings in the period of adjustment. As of March 31, 2024, the Company did not have any material adjustments to variable consideration estimates based on actual results. These specific adjustments are detailed further in the Company's Annual Report on Form 10-K for the year ended December 31, 2023. |
Major Customers | Major Customers: |
Accounts Receivable, Net | Accounts Receivable, net: Accounts receivable are stated at their net realizable value. The Company's accounts receivable primarily represent amounts due to the Company from product sales and from its Otsuka collaboration agreement (Note 12). As of March 31, 2024 and December 31, 2023, accounts receivable, net are $28.9 million and $24.1 million, respectively. The Company's standard credit terms range from 30 to 45 days. The Company does not assess whether a contract has a significant financing component if the expectation at contract inception is such that the period between the transfer of the promised good to the customer and receipt of payment will be one year or less. The Company estimates the allowances using the current expected credit loss, or CECL, model. Under the CECL model, the allowances reflect the net amount expected to be collected from the account receivables. Aurinia evaluates the collectability of these cash flows based on the asset’s amortized cost, the risk of loss even when that risk is remote, losses over an asset’s contractual life, and other relevant information available to the Company. Accounts receivable balances are written off against the allowance when it is probable that the receivable will not be collected. Given the nature of the Company's accounts receivable, it determined that an allowance for current expected credit losses was nil as of March 31, 2024 and December 31, 2023. |
Share-Based Compensation | Share-Based Compensation: The Company follows ASC Topic 718, Compensation - Stock Compensation (ASC 718), which requires the measurement and recognition of compensation expense, based on estimated fair values, for all share-based awards made to employees and directors. The Company records compensation expense based on the fair value on the grant date using the graded accelerated vesting method for all share-based payments related to stock options, performance awards (PAs), restricted stock units (RSUs) and purchases under the Company's 2021 Employee Share Purchase Plan (ESPP). The estimated fair value of performance-based awards is measured on the grant date and is recognized when it is determined that it is probable that the performance condition will be achieved. The Company has elected a policy for all share-based awards to estimate forfeitures based on historical forfeiture experience at the time of grant and revise in subsequent periods if actual forfeitures differ from those estimates. |
Restructuring Expenses | Restructuring Expenses: Restructuring expense consists primarily of employee severance, contract termination costs and other costs. Liabilities for costs associated with a restructuring activity are recognized when the liability is incurred and are measured at fair value. According to ASC 420, Exit or Disposal Cost Obligations , one-time employee severance and termination benefits are expensed at the date the entity notifies the employee of the plan, unless the employee must provide future service, in which case the benefits are expensed in the period when the service ends. One-time termination benefits include severance, continuation of health insurance coverage for certain employees, and other benefits such as outplacement support services for a specified period of time. |
Common Shares | Common Shares: The Company’s shares have no par value or stated value and therefore, upon repurchase or issuance of shares, all amounts related to the shares are recorded under common shares on the balance sheet. The value of common shares includes cash amounts paid or received for the shares and the fair value of equity awards and warrants. Amounts for common shares are offset by share issue costs or transactions costs associated with repurchases or equity offerings. |
Recently Adopted Accounting Pronouncements | Recent Accounting Pronouncements In December 2023, the FASB issued final guidance in ASU No. 2023-09, Income Taxes (ASC 740): Improvements to Income Tax Disclosures requiring entities to provide additional information in the rate reconciliation and disclosures about income taxes paid. For public business entities, the guidance is effective for annual periods beginning after December 15, 2024. The Company is not early adopting, and therefore, this ASU is not adopted in the current period. The Company does not expect this ASU to have a material impact on the consolidated financial statements. In November 2023, the FASB issued ASU No. 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures which requires public entities to disclose significant segment expenses regularly provided to the chief operating decision-maker. Public entities with a single reporting segment have to provide all disclosures required by ASC 280, including the significant segment expense disclosures. For public business entities, the guidance is effective for annual periods beginning after December 15, 2023. This ASU does not have a material impact on the consolidated financial statements. |
Summary of Significant Accoun_3
Summary of Significant Accounting Policies (Tables) | 3 Months Ended |
Mar. 31, 2024 | |
Accounting Policies [Abstract] | |
Schedule of Total Revenues, Net From Main Customers | The percentages of total revenues, net from our main customers were as follows: Three months ended March 31, 2024 2023 Two main specialty pharmacies 91% 99% Collaboration partnership 7% —% |
Fair Value Measurements (Tables
Fair Value Measurements (Tables) | 3 Months Ended |
Mar. 31, 2024 | |
Fair Value Disclosures [Abstract] | |
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis | The following table summarizes the financial assets (cash, cash equivalents, restricted cash and investments) measured at fair value on a recurring basis: March 31, 2024 (in thousands) Level 1 Level 2 Level 3 Total Financial assets: Cash, cash equivalents and restricted cash $ 64,459 $ — $ — $ 64,459 Corporate bonds — 23,745 — 23,745 Commercial paper — 38,243 — 38,243 Treasury bills — 134,974 — 134,974 Treasury bonds — 58,690 — 58,690 Total financial assets $ 64,459 $ 255,652 $ — $ 320,111 December 31, 2023 (in thousands) Level 1 Level 2 Level 3 Total Financial assets: Cash, cash equivalents and restricted cash $ 48,875 $ — $ — $ 48,875 Corporate bonds — 33,781 — 33,781 Commercial paper — 39,304 — 39,304 Treasury bills — 122,806 — 122,806 Treasury bonds — 105,924 — 105,924 Total financial assets $ 48,875 $ 301,815 $ — $ 350,690 |
Cash, Cash Equivalents, Restr_2
Cash, Cash Equivalents, Restricted Cash and Investments (Tables) | 3 Months Ended |
Mar. 31, 2024 | |
Investments, Debt and Equity Securities [Abstract] | |
Summary of Cash, Cash Equivalents, Restricted Cash and Investments | March 31, 2024 (in thousands) Amortized Cost Unrealized Gains Unrealized Losses Estimated Fair Value Cash, cash equivalents and restricted cash $ 64,459 $ — $ — $ 64,459 Corporate bonds 23,547 — (3) 23,544 Commercial paper 38,273 — (30) 38,243 Treasury bills 134,984 — (9) 134,975 Treasury bonds 58,697 — (7) 58,690 Total cash, cash equivalents, restricted cash and short-term investments 319,960 — (49) 319,911 Total long-term investment corporate bond 199 1 — 200 Total cash, cash equivalents, restricted cash and investments $ 320,159 $ 1 $ (49) $ 320,111 December 31, 2023 (in thousands) Amortized Cost Unrealized Gains Unrealized Losses Estimated Fair Value Cash, cash equivalents and restricted cash $ 48,875 $ — $ — $ 48,875 Corporate bonds 33,576 4 — 33,580 Commercial paper 39,305 — (1) 39,304 Treasury bills 122,757 49 — 122,806 Treasury bonds 105,903 21 — 105,924 Total cash, cash equivalents, restricted cash and short-term investments 350,416 74 (1) 350,489 Total long-term investment corporate bond 200 1 — 201 Total cash, cash equivalents, restricted cash and investments $ 350,616 $ 75 $ (1) $ 350,690 |
Inventories, net (Tables)
Inventories, net (Tables) | 3 Months Ended |
Mar. 31, 2024 | |
Inventory Disclosure [Abstract] | |
Schedule of Inventories, Net | The components of inventory, net are as follows: (in thousands) March 31, 2024 December 31, 2023 Raw materials $ 1,702 $ 1,746 Work in process 35,994 37,376 Finished goods, net of reserve 2,065 583 Total inventories, net $ 39,761 $ 39,705 |
Prepaid Expenses (Tables)
Prepaid Expenses (Tables) | 3 Months Ended |
Mar. 31, 2024 | |
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract] | |
Schedule of Prepaid Expenses and Other Current Assets | Prepaid expenses are as follows: (in thousands) March 31, 2024 December 31, 2023 Prepaid assets $ 4,707 $ 6,892 Prepaid deposits 2,376 1,345 Prepaid insurance 563 1,249 Total prepaid expenses $ 7,646 $ 9,486 |
Intangible Assets (Tables)
Intangible Assets (Tables) | 3 Months Ended |
Mar. 31, 2024 | |
Goodwill and Intangible Assets Disclosure [Abstract] | |
Schedule of Intangible Assets | The following table summarizes the carrying amount of intangible assets, net of accumulated amortization. March 31, 2024 (in thousands) Gross Carrying Accumulated Net Carrying Patents $ 1,860 $ (1,307) $ 553 Acquired intellectual property and reacquired rights 15,126 (10,937) 4,189 Internal-use software implementation costs 2,873 (2,855) 18 $ 19,859 $ (15,099) $ 4,760 December 31, 2023 (in thousands) Gross Carrying Accumulated Net Carrying Patents $ 1,847 $ (1,297) $ 550 Acquired intellectual property and reacquired rights 15,126 (10,737) 4,389 Internal-use software implementation costs 2,873 (2,835) 38 $ 19,846 $ (14,869) $ 4,977 |
Property and Equipment, net (Ta
Property and Equipment, net (Tables) | 3 Months Ended |
Mar. 31, 2024 | |
Property, Plant and Equipment [Abstract] | |
Property and Equipment, net | Property and equipment, net are as follows: (in thousands) March 31, 2024 December 31, 2023 Leasehold improvements $ 3,243 $ 3,243 Office equipment 631 631 Furniture 1,155 1,155 Computer equipment 235 235 5,264 5,264 Less accumulated depreciation (2,066) (1,910) Property and equipment, net $ 3,198 $ 3,354 |
Lease Obligations (Tables)
Lease Obligations (Tables) | 3 Months Ended |
Mar. 31, 2024 | |
Leases [Abstract] | |
Lease, Cost | The following table represents the weighted-average remaining lease terms and discount rates as of March 31, 2024: As of March 31, 2024 Weighted Average Remaining Lease Term (years) Weighted Average Discount Rate Operating leases 7.4 5.28% Finance lease 6.0 6.19% Supplemental cash flow information related to leases are as follows: Three months ended 2024 2023 (in thousands) Cash paid for amounts included in the measurement of lease liabilities Financing cash flows from finance lease $ (2,778) $ — Operating cash flows from finance lease $ (1,370) $ — Operating cash flows from operating leases $ (276) $ (263) Supplemental disclosure of noncash transactions Finance right-of-use asset obtained in exchange for lease obligations (monoplant) $ 104,359 $ — Finance lease liability arising from obtaining right-of-use assets (monoplant) $ 81,199 $ — |
Lessee, Operating Lease, Liability, Maturity | Future maturities of lease liabilities as of March 31, 2024 are as follows: (in thousands) Finance Lease Payments Operating Lease Payments Remainder of 2024 $ 12,052 $ 838 2025 16,070 1,141 2026 16,070 1,169 2027 16,070 1,198 2028 16,070 1,227 Thereafter 20,087 3,303 Total lease payments 96,419 8,876 Less: imputed interest (15,220) (1,538) Total $ 81,199 $ 7,338 |
Accounts Payable and Accrued _2
Accounts Payable and Accrued Liabilities (Tables) | 3 Months Ended |
Mar. 31, 2024 | |
Payables and Accruals [Abstract] | |
Schedule of Accrued Liabilities | Accounts payable and accrued liabilities are as follows: (in thousands) March 31, 2024 December 31, 2023 Employee accruals $ 11,412 $ 22,486 Commercial accruals 20,078 16,216 Accrued R&D projects 2,665 5,503 Trade payables 5,672 4,327 Restructuring accruals 2,070 — Other accrued liabilities 6,965 5,190 Income taxes payable 1,408 667 Total accounts payable and accrued liabilities $ 50,270 $ 54,389 |
Net Loss per Common Share (Tabl
Net Loss per Common Share (Tables) | 3 Months Ended |
Mar. 31, 2024 | |
Earnings Per Share [Abstract] | |
Schedule of Loss Per Share, Basic and Diluted | The numerator and denominator used in the calculation of basic and diluted net loss per common share are as follows: Three months ended March 31, (in thousands, except per share data) 2024 2023 Net loss $ (10,749) $ (26,206) Weighted average common shares outstanding 144,013 142,641 Net loss per common share (expressed in $ per share) $ (0.07) $ (0.18) |
Schedule of Antidilutive Securities Excluded from Computation of Loss Per Share | The Company did not include the securities in the following table in the computation of the net loss per common share because the effect would have been anti-dilutive during each period: Three months ended March 31, (in thousands) 2024 2023 Stock options 11,081 12,678 Unvested performance awards 1,503 921 Unvested restricted stock units 7,326 6,983 19,910 20,582 |
Share-based Compensation (Table
Share-based Compensation (Tables) | 3 Months Ended |
Mar. 31, 2024 | |
Share-Based Payment Arrangement [Abstract] | |
Schedule of Share-based Payment Award Valuation Assumptions | The following weighted average assumptions were used to estimate the fair value of the options granted during the three months ended March 31, 2024 and March 31, 2023: 2024 2023 Annualized volatility 77 % 71 % Risk-free interest rate 4.04 % 4.08 % Expected life of options in years 5.0 years 5.0 years Estimated forfeiture rate 13.1 % 12.7 % Dividend rate 0.0 % 0.0% Fair value per common share option $ 4.62 $ 5.44 |
Schedule of Option Activity | The following table summarizes the option award activity for the three months ended March 31, 2024: March 31, 2024 Number of shares (in thousands) Weighted average exercise price $ Outstanding - December 31, 2023 11,556 $ 10.63 Granted 63 7.12 Exercised (6) 4.85 Forfeited or cancelled (532) 11.62 Outstanding - March 31, 2024 11,081 $ 10.57 |
Schedule of Performance Shares Activity | The following table summarizes the RSU and PA activity for the three months ended March 31, 2024: March 31, 2024 Number of shares (in thousands) Weighted average fair value price $ Unvested balance, December 31, 2023 7,807 $ 9.29 Granted 4,491 6.94 Vested (2,225) 9.48 Forfeited (1,244) 9.12 Unvested balance, March 31, 2024 8,829 $ 8.07 |
Allocation of Share-Based Payments | The Company recognized share-based compensation expense for the three months ended March 31, 2024 and March 31, 2023 as follows: Three months ended (in thousands) 2024 2023 Research and development $ (2,166) $ 1,590 Selling, general and administrative 7,537 7,589 Capitalized under inventories 366 288 Share-based compensation expense $ 5,737 $ 9,467 |
Restructuring (Tables)
Restructuring (Tables) | 3 Months Ended |
Mar. 31, 2024 | |
Restructuring and Related Activities [Abstract] | |
Restructuring and Related Costs | As of March 31, 2024, the restructuring expenses recorded by the Company were as follows: (in thousands) Three months ended March 31, 2024 Employee severance and one time benefits $ 5,207 Contract terminations 919 Other costs 557 Total $ 6,683 |
Organization and Description _2
Organization and Description of Business (Details) | 3 Months Ended |
Mar. 31, 2024 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
Number of positions eliminated, percent | 25% |
Summary of Significant Accoun_4
Summary of Significant Accounting Policies- Narrative (Details) | 3 Months Ended | |
Mar. 31, 2024 USD ($) segment | Dec. 31, 2023 USD ($) | |
Property, Plant and Equipment [Line Items] | ||
Number of operating segments | segment | 1 | |
Number of customers | segment | 2 | |
Accounts receivable, net | $ | $ 28,909,000 | $ 24,089,000 |
Allowance for doubtful accounts | $ | $ 0 | $ 0 |
Minimum | ||
Property, Plant and Equipment [Line Items] | ||
Receivable standard credit terms (in days) | 30 days | |
Maximum | ||
Property, Plant and Equipment [Line Items] | ||
Receivable standard credit terms (in days) | 45 days |
Summary of Significant Accoun_5
Summary of Significant Accounting Policies - Schedule of Total Revenues, Net From Main Customers (Details) - Two Specialty Pharmacy - Revenue Benchmark - Customer Concentration Risk | 3 Months Ended | |
Mar. 31, 2024 | Mar. 31, 2023 | |
Product revenue, net | ||
Property, Plant and Equipment [Line Items] | ||
Concentration risk (as percent) | 91% | 99% |
License, collaboration and royalty revenue | ||
Property, Plant and Equipment [Line Items] | ||
Concentration risk (as percent) | 7% | 0% |
Fair Value Measurements - Asset
Fair Value Measurements - Assets and Liabilities Measured on a Recurring Basis (Details) - USD ($) $ in Thousands | 3 Months Ended | 12 Months Ended |
Mar. 31, 2024 | Dec. 31, 2023 | |
Financial assets: | ||
Total financial assets | $ 320,111 | $ 350,690 |
Cash, cash equivalents and restricted cash | ||
Financial assets: | ||
Total financial assets | 64,459 | 48,875 |
Corporate bonds | ||
Financial assets: | ||
Total financial assets | 23,745 | 33,781 |
Commercial paper | ||
Financial assets: | ||
Total financial assets | 38,243 | 39,304 |
Treasury bills | ||
Financial assets: | ||
Total financial assets | 134,974 | 122,806 |
Treasury bonds | ||
Financial assets: | ||
Total financial assets | 58,690 | 105,924 |
Level 1 | ||
Financial assets: | ||
Total financial assets | 64,459 | 48,875 |
Level 1 | Cash, cash equivalents and restricted cash | ||
Financial assets: | ||
Total financial assets | 64,459 | 48,875 |
Level 1 | Corporate bonds | ||
Financial assets: | ||
Total financial assets | 0 | 0 |
Level 1 | Commercial paper | ||
Financial assets: | ||
Total financial assets | 0 | 0 |
Level 1 | Treasury bills | ||
Financial assets: | ||
Total financial assets | 0 | 0 |
Level 1 | Treasury bonds | ||
Financial assets: | ||
Total financial assets | 0 | 0 |
Level 2 | ||
Financial assets: | ||
Total financial assets | $ 255,652 | $ 301,815 |
Derivative, average remaining maturity | 6 months | 7 months |
Level 2 | Cash, cash equivalents and restricted cash | ||
Financial assets: | ||
Total financial assets | $ 0 | $ 0 |
Level 2 | Corporate bonds | ||
Financial assets: | ||
Total financial assets | 23,745 | 33,781 |
Level 2 | Commercial paper | ||
Financial assets: | ||
Total financial assets | 38,243 | 39,304 |
Level 2 | Treasury bills | ||
Financial assets: | ||
Total financial assets | 134,974 | 122,806 |
Level 2 | Treasury bonds | ||
Financial assets: | ||
Total financial assets | 58,690 | 105,924 |
Level 3 | ||
Financial assets: | ||
Total financial assets | 0 | 0 |
Level 3 | Cash, cash equivalents and restricted cash | ||
Financial assets: | ||
Total financial assets | 0 | 0 |
Level 3 | Corporate bonds | ||
Financial assets: | ||
Total financial assets | 0 | 0 |
Level 3 | Commercial paper | ||
Financial assets: | ||
Total financial assets | 0 | 0 |
Level 3 | Treasury bills | ||
Financial assets: | ||
Total financial assets | 0 | 0 |
Level 3 | Treasury bonds | ||
Financial assets: | ||
Total financial assets | $ 0 | $ 0 |
Cash, Cash Equivalents, Restr_3
Cash, Cash Equivalents, Restricted Cash and Investments - Narrative (Details) - USD ($) $ in Thousands | 3 Months Ended | ||
Mar. 31, 2024 | Mar. 31, 2023 | Dec. 31, 2023 | |
Investments, Debt and Equity Securities [Abstract] | |||
Cash, cash equivalents, restricted cash and investments | $ 320,100 | $ 350,700 | |
Available-for-sale debt securities | 255,700 | 301,800 | |
Interest receivable | 1,000 | $ 700 | |
Unrealized gain (loss) on available-for-sale securities | $ (124) | $ 73 |
Cash, Cash Equivalents, Restr_4
Cash, Cash Equivalents, Restricted Cash and Investments - Investments (Details) - USD ($) $ in Thousands | Mar. 31, 2024 | Dec. 31, 2023 |
Marketable Securities [Line Items] | ||
Amortized Cost | $ 319,960 | $ 350,416 |
Unrealized Gains | 0 | 74 |
Unrealized Losses | (49) | (1) |
Estimated Fair Value | 319,911 | 350,489 |
Total cash, cash equivalents, restricted cash and investments, Amortized Cost | 320,159 | 350,616 |
Total cash, cash equivalents, restricted cash and investments, unrealized gains | 1 | 75 |
Total cash, cash equivalents, restricted cash and investments, unrealized losses | (49) | (1) |
Total cash, cash equivalents, restricted cash and investments | 320,111 | 350,690 |
Cash, cash equivalents and restricted cash | ||
Marketable Securities [Line Items] | ||
Amortized Cost | 64,459 | 48,875 |
Unrealized Gains | 0 | 0 |
Unrealized Losses | 0 | 0 |
Estimated Fair Value | 64,459 | 48,875 |
Corporate bonds | ||
Marketable Securities [Line Items] | ||
Amortized Cost | 23,547 | 33,576 |
Unrealized Gains | 0 | 4 |
Unrealized Losses | (3) | 0 |
Estimated Fair Value | 23,544 | 33,580 |
Commercial paper | ||
Marketable Securities [Line Items] | ||
Amortized Cost | 38,273 | 39,305 |
Unrealized Gains | 0 | 0 |
Unrealized Losses | (30) | (1) |
Estimated Fair Value | 38,243 | 39,304 |
Treasury bills | ||
Marketable Securities [Line Items] | ||
Amortized Cost | 134,984 | 122,757 |
Unrealized Gains | 0 | 49 |
Unrealized Losses | (9) | 0 |
Estimated Fair Value | 134,975 | 122,806 |
Treasury bonds | ||
Marketable Securities [Line Items] | ||
Amortized Cost | 58,697 | 105,903 |
Unrealized Gains | 0 | 21 |
Unrealized Losses | (7) | 0 |
Estimated Fair Value | 58,690 | 105,924 |
Total long-term investment corporate bond | ||
Marketable Securities [Line Items] | ||
Amortized Cost | 199 | 200 |
Unrealized Gains | 1 | 1 |
Unrealized Losses | 0 | 0 |
Estimated Fair Value | $ 200 | $ 201 |
Inventories, net (Details)
Inventories, net (Details) - USD ($) $ in Thousands | Mar. 31, 2024 | Dec. 31, 2023 |
Inventory Disclosure [Abstract] | ||
Finished goods inventories | $ 500 | $ 800 |
Raw materials | 1,702 | 1,746 |
Work in process | 35,994 | 37,376 |
Finished goods, net of reserve | 2,065 | 583 |
Total inventories, net | $ 39,761 | $ 39,705 |
Prepaid Expenses (Details)
Prepaid Expenses (Details) - USD ($) $ in Thousands | Mar. 31, 2024 | Dec. 31, 2023 |
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract] | ||
Prepaid assets | $ 4,707 | $ 6,892 |
Prepaid deposits | 2,376 | 1,345 |
Prepaid insurance | 563 | 1,249 |
Total prepaid expenses | $ 7,646 | $ 9,486 |
Intangible Assets - Schedule of
Intangible Assets - Schedule of Intangible Assets (Details) - USD ($) $ in Thousands | Mar. 31, 2024 | Dec. 31, 2023 |
Finite-Lived Intangible Assets [Line Items] | ||
Gross Carrying Value | $ 19,859 | $ 19,846 |
Accumulated Amortization | (15,099) | (14,869) |
Net Carrying Amount | 4,760 | 4,977 |
Patents | ||
Finite-Lived Intangible Assets [Line Items] | ||
Gross Carrying Value | 1,860 | 1,847 |
Accumulated Amortization | (1,307) | (1,297) |
Net Carrying Amount | 553 | 550 |
Acquired intellectual property and reacquired rights | ||
Finite-Lived Intangible Assets [Line Items] | ||
Gross Carrying Value | 15,126 | 15,126 |
Accumulated Amortization | (10,937) | (10,737) |
Net Carrying Amount | 4,189 | 4,389 |
Internal-use software implementation costs | ||
Finite-Lived Intangible Assets [Line Items] | ||
Gross Carrying Value | 2,873 | 2,873 |
Accumulated Amortization | (2,855) | (2,835) |
Net Carrying Amount | $ 18 | $ 38 |
Intangible Assets - Narrative (
Intangible Assets - Narrative (Details) - USD ($) $ in Millions | 3 Months Ended | |
Mar. 31, 2024 | Mar. 31, 2023 | |
Goodwill and Intangible Assets Disclosure [Abstract] | ||
Amortization of intangible assets | $ 0.2 | $ 0.5 |
Property and Equipment, net (De
Property and Equipment, net (Details) - USD ($) $ in Thousands | Mar. 31, 2024 | Dec. 31, 2023 |
Property, Plant and Equipment [Line Items] | ||
Property, plant and equipment, gross | $ 5,264 | $ 5,264 |
Less accumulated depreciation | (2,066) | (1,910) |
Property and equipment, net | 3,198 | 3,354 |
Leasehold improvements | ||
Property, Plant and Equipment [Line Items] | ||
Property, plant and equipment, gross | 3,243 | 3,243 |
Office equipment | ||
Property, Plant and Equipment [Line Items] | ||
Property, plant and equipment, gross | 631 | 631 |
Furniture | ||
Property, Plant and Equipment [Line Items] | ||
Property, plant and equipment, gross | 1,155 | 1,155 |
Computer equipment | ||
Property, Plant and Equipment [Line Items] | ||
Property, plant and equipment, gross | $ 235 | $ 235 |
Lease Obligations - Narrative (
Lease Obligations - Narrative (Details) $ in Thousands | 1 Months Ended | 3 Months Ended | 12 Months Ended | ||||
Mar. 31, 2020 ft² extension_option | Mar. 31, 2024 USD ($) | Mar. 31, 2023 USD ($) | Dec. 31, 2023 USD ($) | Jul. 31, 2023 USD ($) | Oct. 31, 2022 ft² | Mar. 12, 2020 | |
Lessee, Lease, Description [Line Items] | |||||||
Operating right-of-use assets, net | $ 4,394 | $ 4,498 | |||||
Total | $ 7,338 | ||||||
Operating lease, weighted average discount rate | 5.28% | ||||||
Operating lease costs | $ 200 | $ 200 | |||||
Finance right-of-use asset, net | 104,358 | 108,715 | |||||
Finance lease, liability | $ 81,199 | ||||||
Finance lease, weighted average discount rate | 6.19% | ||||||
Rockville, Maryland | |||||||
Lessee, Lease, Description [Line Items] | |||||||
Area of property (in sqft) | ft² | 30,531 | ||||||
Remaining lease term | 7 years | ||||||
Number of extension options | extension_option | 2 | ||||||
Lease extension term | 5 years | ||||||
Lease term | 11 years | ||||||
Lease termination option term | 7 years | ||||||
Operating right-of-use assets, net | $ 4,400 | 4,500 | |||||
Total | 7,200 | 7,400 | |||||
Proceeds from tenant improvements | 2,300 | ||||||
Operating lease, weighted average discount rate | 5.20% | ||||||
Edmonton, Alberta | |||||||
Lessee, Lease, Description [Line Items] | |||||||
Area of property (in sqft) | ft² | 4,375 | ||||||
Remaining lease term | 6 years | ||||||
Lease extension term | 5 years | ||||||
Monoplant | |||||||
Lessee, Lease, Description [Line Items] | |||||||
Finance right-of-use asset, net | 104,400 | 108,700 | $ 117,600 | ||||
Finance lease, liability | 81,200 | $ 90,100 | $ 94,100 | ||||
Finance lease, weighted average discount rate | 6.19% | ||||||
Finance lease, right-of-use asset, amortization | 4,400 | ||||||
Interest expense | 1,300 | ||||||
Beinheim | |||||||
Lessee, Lease, Description [Line Items] | |||||||
Expected payments prior to commencement of lease | 1,000 | ||||||
Future value of minimum lease payments of leases not yet commenced | $ 100 |
Lease Obligations - Summary of
Lease Obligations - Summary of Components of Leasing Costs and Rent (Details) - USD ($) $ in Thousands | 3 Months Ended | |
Mar. 31, 2024 | Mar. 31, 2023 | |
Leases [Abstract] | ||
Operating lease, weighted average remaining lease term (years) | 7 years 4 months 24 days | |
Operating lease, weighted average discount rate | 5.28% | |
Finance lease, operating lease, weighted average remaining lease term (years) | 6 years | |
Finance lease, weighted average discount rate | 6.19% | |
Cash paid for amounts included in the measurement of lease liabilities | ||
Financing cash flows from finance lease | $ (2,778) | $ 0 |
Operating cash flows from finance lease | (1,370) | 0 |
Operating cash flows from operating leases | (276) | (263) |
Supplemental cash flow information | ||
Finance right-of-use asset obtained in exchange for lease obligations (monoplant) | 104,359 | 0 |
Finance lease liability arising from obtaining right-of-use assets (monoplant) | $ 81,199 | $ 0 |
Lease Obligations - Schedule of
Lease Obligations - Schedule of Maturities of Lease Liabilities (Details) $ in Thousands | Mar. 31, 2024 USD ($) |
Finance Lease Payments | |
Remainder of 2024 | $ 12,052 |
2025 | 16,070 |
2026 | 16,070 |
2027 | 16,070 |
2028 | 16,070 |
Thereafter | 20,087 |
Total lease payments | 96,419 |
Less: imputed interest | (15,220) |
Total | 81,199 |
Operating Lease Payments | |
Remainder of 2024 | 838 |
2025 | 1,141 |
2026 | 1,169 |
2027 | 1,198 |
2028 | 1,227 |
Thereafter | 3,303 |
Total lease payments | 8,876 |
Less: imputed interest | (1,538) |
Total | $ 7,338 |
Accounts Payable and Accrued _3
Accounts Payable and Accrued Liabilities (Details) - USD ($) $ in Thousands | Mar. 31, 2024 | Dec. 31, 2023 |
Payables and Accruals [Abstract] | ||
Employee accruals | $ 11,412 | $ 22,486 |
Commercial accruals | 20,078 | 16,216 |
Accrued R&D projects | 2,665 | 5,503 |
Trade payables | 5,672 | 4,327 |
Restructuring accruals | 2,070 | 0 |
Other accrued liabilities | 6,965 | 5,190 |
Income taxes payable | 1,408 | 667 |
Total accounts payable and accrued liabilities | $ 50,270 | $ 54,389 |
Accounts Payable and Accrued _4
Accounts Payable and Accrued Liabilities - Narrative (Details) $ in Millions | Mar. 31, 2024 USD ($) |
Payables and Accruals [Abstract] | |
Restructuring reserve, accrual adjustment | $ 2.1 |
Deferred Compensation and Oth_2
Deferred Compensation and Other Non-current Liabilities (Details) - USD ($) $ in Thousands | Mar. 31, 2024 | Dec. 31, 2023 |
Payables and Accruals [Abstract] | ||
Other non-current liabilities | $ 12,292 | $ 10,911 |
License and Collaboration Agr_2
License and Collaboration Agreements (Details) - USD ($) $ in Thousands | 3 Months Ended | 12 Months Ended | |||
Nov. 13, 2023 | Mar. 31, 2024 | Mar. 31, 2023 | Mar. 31, 2021 | Dec. 31, 2020 | |
Research and Development Arrangement, Contract to Perform for Others [Line Items] | |||||
Revenues | $ 50,303 | $ 34,409 | |||
Otuska | License Agreement Terms | |||||
Research and Development Arrangement, Contract to Perform for Others [Line Items] | |||||
Upfront payments received | $ 50,000 | ||||
Regulatory and pricing approval milestone revenue | $ 40,000 | ||||
Eligible to receive a payment | $ 10,000 | ||||
Otuska | License Agreement Terms | Service Revenue | |||||
Research and Development Arrangement, Contract to Perform for Others [Line Items] | |||||
Revenues | $ 2,200 | $ 100 | |||
Otuska | License Agreement Terms | Minimum | |||||
Research and Development Arrangement, Contract to Perform for Others [Line Items] | |||||
Tiered royalty percentages on future sales | 10% | ||||
Otuska | License Agreement Terms | Maximum | |||||
Research and Development Arrangement, Contract to Perform for Others [Line Items] | |||||
Tiered royalty percentages on future sales | 20% |
Shareholder's Equity (Details)
Shareholder's Equity (Details) $ in Millions | 3 Months Ended | |
Feb. 29, 2024 USD ($) | Mar. 31, 2024 USD ($) shares | |
Class of Stock [Line Items] | ||
Stock repurchase program, authorized amount | $ 150 | |
Stock repurchase program, percentage | 0.15 | |
Stock repurchased during period, (in shares) | shares | (2,400,000) | |
Stock repurchased during period, value | $ (13.4) | |
Minimum | ||
Class of Stock [Line Items] | ||
Stock repurchase program, period | 12 months | |
Maximum | ||
Class of Stock [Line Items] | ||
Stock repurchase program, period | 36 months |
Net Loss per Common Share - Sch
Net Loss per Common Share - Schedule of Earnings Per Share, Basic and Diluted (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands | 3 Months Ended | |
Mar. 31, 2024 | Mar. 31, 2023 | |
Earnings Per Share [Abstract] | ||
Net loss | $ (10,749) | $ (26,206) |
Weighted average common shares outstanding basic (in shares) | 144,013 | 142,641 |
Weighted average common shares outstanding diluted (in shares) | 144,013 | 142,641 |
Basic Net loss per common share (expressed in usd per share)) | $ (0.07) | $ (0.18) |
Diluted Net loss per common share (expressed in usd per share) | $ (0.07) | $ (0.18) |
Net Loss per Common Share - Ant
Net Loss per Common Share - Anti-Dilutive Securities (Details) - shares shares in Thousands | 3 Months Ended | |
Mar. 31, 2024 | Mar. 31, 2023 | |
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ||
Antidilutive securities excluded from computation of earnings per share (in shares) | 19,910 | 20,582 |
Stock options | ||
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ||
Antidilutive securities excluded from computation of earnings per share (in shares) | 11,081 | 12,678 |
Unvested performance awards | ||
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ||
Antidilutive securities excluded from computation of earnings per share (in shares) | 1,503 | 921 |
Unvested restricted stock units | ||
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ||
Antidilutive securities excluded from computation of earnings per share (in shares) | 7,326 | 6,983 |
Share-based Compensation - Narr
Share-based Compensation - Narrative (Details) - USD ($) $ in Millions | 1 Months Ended | 3 Months Ended |
Jun. 30, 2021 | Mar. 31, 2024 | |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||
Unrecognized share-based compensation expense | $ 40.4 | |
Unrecognized share-based compensation expense weighted average recognition period (in years) | 1 year 7 months 6 days | |
Employee Stock | ||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||
Number of shares authorized | 2,500,000 | |
Number of shares purchased (in shares) | 700,000 | |
Amended and Restated Equity Incentive Plan | ||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||
Number of additional shares authorized | 23,800,000 |
Share-based Compensation - Weig
Share-based Compensation - Weighted Average Assumptions (Details) - USD ($) | 3 Months Ended | |
Mar. 31, 2024 | Mar. 31, 2023 | |
Share-Based Payment Arrangement [Abstract] | ||
Annualized volatility (as percent) | 77% | 71% |
Risk-free interest rate (as percent) | 4.04% | 4.08% |
Expected life of options in years | 5 years | 5 years |
Estimated forfeiture rate (as percent) | 13.10% | 12.70% |
Dividend rate | $ 0 | $ 0 |
Fair value per common share option (in usd per share) | $ 4.62 | $ 5.44 |
Share-based Compensation - Stoc
Share-based Compensation - Stock Option Activity (Details) - $ / shares shares in Thousands | 3 Months Ended | |
Mar. 31, 2024 | Dec. 31, 2023 | |
Number of shares (in thousands) | ||
Beginning balance (in shares) | 11,556 | |
Granted (in shares) | 63 | |
Exercised (in shares) | (6) | |
Forfeited or cancelled (in shares) | (532) | |
Ending balance (in shares) | 11,081 | |
Weighted average exercise price $ | ||
Beginning balance (in usd per share) | $ 10.57 | $ 10.63 |
Granted (in usd per share) | 7.12 | |
Exercised (in usd per share) | 4.85 | |
Forfeited or cancelled (in usd per share) | 11.62 | |
Ending balance (in usd per share) | $ 10.57 |
Share-based Compensation - Perf
Share-based Compensation - Performance Awards and Restricted Stock Units Activity (Details) - Officer - Performance Share sand Restricted Stock Units (RSUs) shares in Thousands | 3 Months Ended |
Mar. 31, 2024 $ / shares shares | |
Number of shares (in thousands) | |
Outstanding - Beginning of Period (in shares) | shares | 7,807 |
Granted (in shares) | shares | 4,491 |
Vested (in shares) | shares | (2,225) |
Forfeited (in shares) | shares | (1,244) |
Outstanding - End of Period (in shares) | shares | 8,829 |
Weighted average exercise price $ | |
Outstanding, Weighted average exercise price - Beginning of Period (in usd per share) | $ / shares | $ 9.29 |
Weighted average grant date fair value (in usd per share) | $ / shares | 6.94 |
Weighted average grant date fair value (in usd per share) | $ / shares | 9.48 |
Weighted average exercise price (in usd per share) | $ / shares | 9.12 |
Outstanding, Weighted average exercise price - End of Period (in usd per share) | $ / shares | $ 8.07 |
Share-based Compensation - Allo
Share-based Compensation - Allocated Share-Based Compensation Expense (Details) - USD ($) $ in Thousands | 3 Months Ended | |
Mar. 31, 2024 | Mar. 31, 2023 | |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||
Share-based compensation expense | $ 5,737 | $ 9,467 |
Research and development | ||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||
Share-based compensation expense | (2,166) | 1,590 |
Selling, general and administrative | ||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||
Share-based compensation expense | 7,537 | 7,589 |
Capitalized under inventories | ||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||
Share-based compensation expense | $ 366 | $ 288 |
Income Taxes (Details)
Income Taxes (Details) - USD ($) $ in Thousands | 3 Months Ended | |
Mar. 31, 2024 | Mar. 31, 2023 | |
Income Tax Disclosure [Abstract] | ||
Income tax (benefit) expense | $ 739 | $ 436 |
Related-Party Transactions (Det
Related-Party Transactions (Details) - USD ($) $ in Thousands | 3 Months Ended | ||
Mar. 31, 2024 | Mar. 31, 2023 | Dec. 31, 2023 | |
Related Party Transaction [Line Items] | |||
Other current liabilities (of which $0.8 million in 2024 and 2023 is due to a related party, respectively) | $ 1,150 | $ 2,388 | |
Other non-current liabilities | 12,292 | 10,911 | |
Dr. Robert T. Foster | |||
Related Party Transaction [Line Items] | |||
Payments of deferred compensation | 100 | $ 100 | |
Employee Benefit Obligations | Dr. Robert T. Foster | |||
Related Party Transaction [Line Items] | |||
Other current liabilities (of which $0.8 million in 2024 and 2023 is due to a related party, respectively) | 800 | 800 | |
Other non-current liabilities | $ 8,800 | $ 7,600 |
Restructuring (Details)
Restructuring (Details) $ in Millions | 3 Months Ended |
Mar. 31, 2024 USD ($) | |
Restructuring Cost and Reserve [Line Items] | |
Reduce employee headcount percentage | 25% |
Number of positions eliminated, percent | 25% |
Other Restructuring | |
Restructuring Cost and Reserve [Line Items] | |
Restructuring and Related Cost, Incurred Cost | $ 6.7 |
Employee Severance | |
Restructuring Cost and Reserve [Line Items] | |
Restructuring and Related Cost, Incurred Cost | 6.7 |
Contract Termination | |
Restructuring Cost and Reserve [Line Items] | |
Restructuring and Related Cost, Incurred Cost | $ 6.7 |
Restructuring - Restructuring a
Restructuring - Restructuring and Related Costs (Details) $ in Thousands | 3 Months Ended |
Mar. 31, 2024 USD ($) | |
Restructuring Cost and Reserve [Line Items] | |
Restructuring costs and asset impairment charges | $ 6,683 |
Employee Severance | |
Restructuring Cost and Reserve [Line Items] | |
Restructuring costs and asset impairment charges | 5,207 |
Contract Termination | |
Restructuring Cost and Reserve [Line Items] | |
Restructuring costs and asset impairment charges | 919 |
Other Restructuring | |
Restructuring Cost and Reserve [Line Items] | |
Restructuring costs and asset impairment charges | $ 557 |
Subsequent Events (Details)
Subsequent Events (Details) - USD ($) $ in Millions | 1 Months Ended | 3 Months Ended |
Apr. 30, 2024 | Mar. 31, 2024 | |
Subsequent Event [Line Items] | ||
Stock repurchased during period, (in shares) | 2,400,000 | |
Stock repurchased during period, value | $ 13.4 | |
Subsequent Event | ||
Subsequent Event [Line Items] | ||
Stock repurchased during period, (in shares) | 1,000,000 | |
Stock repurchased during period, value | $ 5.2 |